The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease
Open accessAbstract
The distribution and tempo of neuronal loss in Parkinson's disease correlates poorly with the characteristic and more widely spread intracellular changes associated with the disease process (Lewy bodies and Lewy neurites). To determine early intracellular changes in regions where cell loss is most marked (dopaminergic A9 substantia nigra) versus regions with Lewy bodies but where cell loss is limited, we assessed 13 patients with definite Parkinson's disease at various disease stages in comparison with controls. Using immunohistochemistry for alpha-synuclein, we confirmed the concentration of this protein in the soma of normal A9 neurons and in Lewy body pathology in brainstem catecholamine neurons in Parkinson's disease. Analysis of the degree of cell loss in brainstem catecholamine cell groups revealed that only the A9 substantia nigra had consistent significant cell loss early in the disease course with greater A9 cell loss correlating with increasing disease duration. To assess the earliest intracellular changes differentiating neurons more likely to degenerate, pigmented A9 and A10 neurons with and without obvious pathology were targeted, cell size and pigment density measured, and intracellular changes in alpha-synuclein location and lipid components analysed at both the light and electron microscope levels. There were no changes observed in healthy A10 neurons in Parkinson's disease compared with controls. Pigmented A9 neurons in later stages of degeneration with obvious Lewy body formation had a significant reduction in intracellular pigment, as previously described. In contrast, A9 neurons of normal morphological appearance and no characteristic pathology in Parkinson's disease exhibited significantly increased pigment density associated with a concentration of alpha-synuclein to the lipid component of the pigment and a loss of associated cholesterol. These changes in vulnerable but apparently healthy A9 neurons occurred without any change in cell size or in the amount of intracellular pigment compared with controls. The increase in pigment density is consistent with previously reported increases associated with oxidation and iron loading, reactions known to precipitate alpha-synuclein. The selectivity of the changes observed in A9 nigral neurons suggests that these early intracellular changes predispose these neurons to more rapid cell loss in Parkinson's disease. The increased concentration of neuronal alpha-synuclein and pigment in normal A9 neurons may already predispose these neurons to precipitate alpha-synuclein around pigment-associated lipid under oxidative conditions. Overall, these changes may trigger a cascade of events leading to larger intracellular aggregates of alpha-synuclein and the dispersement of protective pigment to precipitate cell death in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 5×
“Parkinson's disease is the most common neurodegenerative movement disorder characterized by a progressive cellular deposition of the synaptic protein a-synuclein in diverse brain regions (Braak et al., 2003).”
BackgroundMethodInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“…SN are uniquely vulnerable to inflammatory attack and oxidative injury, as there is a naturally high density of inflammatory microglia in the SN (Lawson et al., 1990; Kim et al., 2000) and dopamine production and use depend on oxidative mechanisms (Jenner and Olanow, 1998; Faucheux et al.,…”
BackgroundMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 6×
“In humans, an obvious difference between A9 and other dopamineand non-dopamine-containing neurons in the brain is the increased pigmentation found in this cell group (Mann and Yates, 1983; Hirsch et al., 1988; Gibb, 1992; Kastner et al., 1992).”
BackgroundResultInfluentialEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313 · cited 1×
“…with increased Fe 3+ in Parkinson's disease (Faucheux et al., 2003), suggesting increased cellular oxidation and the saturation of NM's metalchelating properties in Parkinson's disease (Jellinger et al., 1992; Kienzl et al., 1999; Double et al., 2002; Faucheux et al., 2003; Zecca et al., 2003).”
Background
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Self-citationAgeing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease
Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778
Self-citationNeuropathology of Parkinson disease
Dickson, D. W. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.033 · Cited by 623
Environmental Toxins and Parkinson's Disease
Goldman, S. M. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135937 · Cited by 505
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
C. elegans Model Identifies Genetic Modifiers of α-Synuclein Inclusion Formation During Aging
van Ham, T. J., Thijssen, K. L., Breitling, R., Hofstra, R. M. W., Plasterk, R. H. A., & Nollen, E. A. A. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000027 · Cited by 427
Acceleration of α-Synuclein Aggregation by Exosomes
Grey, M., Dunning, C. J., Gaspar, R., Grey, C., Brundin, P., Sparr, E., & Linse, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.585703 · Cited by 377
Research in motion: the enigma of Parkinson's disease pathology spread
Brundin, P., Li, J.-Y., Holton, J. L., Lindvall, O., & Revesz, T. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2477 · Cited by 328
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
Selenium, selenoproteins and neurodegenerative diseases
Cardoso, B. R., Roberts, B. R., Bush, A. I., & Hare, D. J. (2015) · Metallomics · doi:10.1039/c5mt00075k · Cited by 295
Iron and dopamine: a toxic couple
Hare, D. J., & Double, K. L. (2016) · Brain · doi:10.1093/brain/aww022 · Cited by 283
Self-citationCopper pathology in vulnerable brain regions in Parkinson's disease
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244
“We have previously shown that the earliest deposition of a-synuclein in the parkinsonian SN occurs on NM (Halliday et al., 2005), and both regional and NM-associated Cu levels are significantly higher in the normal SN and LC compared with other brain regions (Bohic et al.”
BackgroundSelf-citationJyothi, H. J., Vidyadhara, D. J., Mahadevan, A., Philip, M., Parmar, S. K., Manohari, S. G., Shankar, S. K., Raju, T. R., & Alladi, P. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.024 · Cited by 139
Role of Sphingolipid Metabolism in Neurodegeneration
Alaamery, M., Albesher, N., Aljawini, N., Alsuwailm, M., Massadeh, S., Wheeler, M. A., Chao, C., & Quintana, F. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15044 · Cited by 129
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Viereckel, T., Dumas, S., Smith-Anttila, C. J. A., Vlcek, B., Bimpisidis, Z., Lagerström, M. C., Konradsson-Geuken, Å., & Wallén-Mackenzie, Å. (2016) · Scientific Reports · doi:10.1038/srep35203 · Cited by 45
APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease
Singh, N. K., Banerjee, B. D., Bala, K., Mitrabasu, Dung Dung, A. A., & Chhillar, N. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1651-6 · Cited by 31
Metadata
- Authors
- Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., Cartwright, M. I., Griffiths, F. M., Shepherd, C. E., & Double, K. L.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-06
- Volume
- 128
- Issue
- 11
- Pages
- 2654-2664
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2124010317
- Cited by
- 219
- References
- 14
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.